Sotorasib (re-assessment: non-small cell lung cancer (NSCLC); KRAS G12C mutation; ≥ 1 previous therapy)

Subject:

• Active Substance: Sotorasib
• Name: Lumykras®
• Therapeutic area: Non-small cell lung cancer (NSCLC)
• Pharmaceutical company: Amgen Europe B.V.

Time table:

• Start: 01.02.2023
• Final decision by G-BA: 03.08.2023

Final decision:

2. Patients with a cytotoxic chemotherapy as first-line therapy: No additional benefit proved
    
3. After first-line therapy with a PD-1/PD-L1 antibody in combination with platinum-containing chemotherapy or after sequential therapy with a PD-1/PD-L1 antibody and platinum-based chemotherapy as first-line therapy:
   c1) Adults for whom docetaxel is the most appropriate patient-individual therapy: Hint for a non-quantifiable additional benefit 
   c2) Adults for whom other therapies than docetaxel are the most appropriate patient-individual therapies: No additional benefit proved